KR-31372 inhibits KDR/Flk-1 tyrosine phosphorylation via K+ATP channel opening in its antiangiogenic effect

European Journal of Pharmacology

Volumn 465, Issue 3, 2003, Pages 219-228

  Kim, Ki Young ^a   Kim, Sun Ok ^b   Lim, Hong ^b   Yoo, Sung Eun ^c   Hong, Ki Whan ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Dongbu Hannong Chemical Co   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Endothelial cell, umbilical vein, human; K+ channel opener, ATP sensitive; KDR Flk 1; KR 31372; p125FAK; VEGF (vascular endothelial growth factor)

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; BROMODEOXYCYTIDINE; CELL ADHESION MOLECULE; GLIBENCLAMIDE; GUANIDINE DERIVATIVE; ISOENZYME; KR 31372; LEMAKALIM; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; N'' CYANO N (6 NITRO 3,4 DIHYDROHYDROXY 2 METHYL 2 DIMETHOXYMETHYL 2H 1 BENZOPYRAN 4 YL) N' BENZYLGUANIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; PROTEIN; PROTEIN P125; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 12244310131     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01493-6     Document Type: Article

References (28)

1. Abedi H., Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc. Res. 30:1995;544-556.
2. Abedy H., Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 272:1997;15442-15451.
3. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:1995;27489-27494.
4. Ashcroft F.M., Gribble F.M. New windows on the mechanism of action of K(ATP) channel openers. Trends Pharmacol. Sci. 21:2000;439-445.
5. Cao Y., Ji R.W., Davidson D., Schaller J., Marti D., Sohndel S., McCance S.G., O-Reilly M.S., Llinas M., Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271:1996;29461-29467.
6. Debska G., Kicinska A., Skalska J., Szewczyk A., May R., Elger C.E., Kunz W.S. Opening of potassium channels modulates mitochodrial function in rat skeletal muscle. Biochim. Biophys. Acta. 1556:2002;97-105.
7. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:1997;4-25.
8. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 267:1992;10931-10934.
9. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
10. Hamilton T.C., Weir S.W., Weston A.H. Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br. J. Pharmacol. 88:1986;103-111.
11. + channel opener, in comparison with levcromakalim. Pharmacol. Res. 38:1998;191-197.
12. Kanno S., Oda N., Abe M., Terai Y., Ito M., Shitara K., Tabayashi K., Shibuya M., Sato Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene. 19:2000;2138-2146.
13. 2+ signal and tube formation induced by vascular endothelial growth factor in bovine aortic endothelial cells. Eur. J. Pharmacol. 398:2000;19-29.
14. Kim H.H., Ha H.J., Kim S.-O., Kim S.-K., Yoo S.-E., Hong K.W. KR-31372 exerts antioxidative action with inhibition of oxidized LDL-stimulated proliferation and migration of vascular smooth muscle cells. Fundam. Clin. Pharmacol. 14:2000;469-476.
15. Kim C.D., Kim H.H., Kim Y.K., Kwak Y.K., Kim S.-O., Yoo S.-E., Hong K.W. Antiangiogenic effect of KR-31372 in rat sponge implant model. J. Pharmacol. Exp. Ther. 296:2001;1085-1090.
16. Kohn E.C., Alessandro R., Spoonster J., Wersto R.P., Liotta L.A. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1307-1311.
17. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272:1997;32521-32527.
18. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846.
19. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:1999;9-22.
20. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100:1997;3131-3139.
21. Quinn T.P., Peters K.G., De Vries C., Ferrara N., Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. U. S. A. 90:1993;7533-7537.
22. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
23. Rousseau S., Houle F., Landry J., Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 15:1997;2169-2177.
24. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 10:1995;135-147.
25. Shen B.Q., Lee D.Y., Zioncheck T.F. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J. Biol. Chem. 274:1999;33057-33063.
26. Stepien O., Gogusev J., Zhu D.L., Iouzalen L., Herembert T., Drueke T.B., Marche P. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J. Cardiovasc. Pharmacol. 31:1998;786-793.
27. Takahashi T., Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene. 14:1997;2079-2089.
28. Yu Y., Sato J.D. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J. Cell Physiol. 178:1999;235-246.